Literature DB >> 22066036

Efficacy of trabectedin in metastatic solitary fibrous tumor.

Loïc Chaigneau1, Elsa Kalbacher, Antoine Thiery-Vuillemin, Christine Fagnoni-Legat, Nicolas Isambert, Lionel Aherfi, Julien Pauchot, Delphine Delroeux, Stephanie Servagi-Vernat, Laura Mansi, Xavier Pivot.   

Abstract

Solitary fibrous tumor is a rare tumor type and has an unpredictable course. Local recurrence rate varies between 9 and 19%, and rate of metastatic involvement between 0 and 36 %. It is characterized by a typical architecture and immuno-histochemistry tests. The most important prognostic factor is the complete resection of primary tumor. Treatment of recurrences is not clearly established. If a solitary fibrous tumor is too advanced to allow surgical resection, radiotherapy and chemotherapy may be used. The most often used drugs are doxorubicine and\or ifosfamide. We report the case of man with metastatic solitary fibrous tumor treated with trabectedin, administered at a dose of 1.5 mg/m² every 3 weeks. After 3 cycles, metastases had significantly decreased. Recurrence of the disease was demonstrated 8 months after the start of trabectedin. This case shows that trabectedin is a possible treatment option.

Entities:  

Keywords:  metastatic solitary fibrous tumor; trabectedin.

Year:  2011        PMID: 22066036      PMCID: PMC3208416          DOI: 10.4081/rt.2011.e29

Source DB:  PubMed          Journal:  Rare Tumors        ISSN: 2036-3605


  12 in total

1.  Solitary fibrous tumour arising at unusual sites: analysis of a series.

Authors:  J R Goodlad; C D Fletcher
Journal:  Histopathology       Date:  1991-12       Impact factor: 5.087

2.  Extrapleural solitary fibrous tumor: a clinicopathologic study of 24 cases.

Authors:  R B Brunnemann; J Y Ro; N G Ordonez; J Mooney; A K El-Naggar; A G Ayala
Journal:  Mod Pathol       Date:  1999-11       Impact factor: 7.842

3.  Extrathoracic solitary fibrous tumors: their histological variability and potentially aggressive behavior.

Authors:  T Hasegawa; Y Matsuno; T Shimoda; F Hasegawa; T Sano; S Hirohashi
Journal:  Hum Pathol       Date:  1999-12       Impact factor: 3.466

4.  Lipomatous hemangiopericytoma: a fat-containing variant of solitary fibrous tumor? Clinicopathologic, immunohistochemical, and ultrastructural analysis of a series in favor of a unifying concept.

Authors:  L Guillou; S Gebhard; J M Coindre
Journal:  Hum Pathol       Date:  2000-09       Impact factor: 3.466

5.  Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

Authors:  Bradley J Monk; Thomas J Herzog; Stanley B Kaye; Carolyn N Krasner; Jan B Vermorken; Franco M Muggia; Eric Pujade-Lauraine; Alla S Lisyanskaya; Anatoly N Makhson; Janusz Rolski; Vera A Gorbounova; Prafull Ghatage; Mariusz Bidzinski; Keng Shen; Hextan Yuen-Sheung Ngan; Ignace B Vergote; Joo-Hyun Nam; Youn Choi Park; Claudia A Lebedinsky; Andrés M Poveda
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

6.  Solitary fibrous tumor: histological and immunohistochemical spectrum of benign and malignant variants presenting at different sites.

Authors:  C A Hanau; M Miettinen
Journal:  Hum Pathol       Date:  1995-04       Impact factor: 3.466

Review 7.  ET-743: more than an innovative mechanism of action.

Authors:  Kathleen W Scotto
Journal:  Anticancer Drugs       Date:  2002-05       Impact factor: 2.248

8.  Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases.

Authors:  D M England; L Hochholzer; M J McCarthy
Journal:  Am J Surg Pathol       Date:  1989-08       Impact factor: 6.394

9.  Solitary fibrous tumors of soft tissue. A clinicopathologic and immunohistochemical study of 12 cases.

Authors:  S Suster; A G Nascimento; M Miettinen; J Z Sickel; C A Moran
Journal:  Am J Surg Pathol       Date:  1995-11       Impact factor: 6.394

10.  Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.

Authors:  George D Demetri; Sant P Chawla; Margaret von Mehren; Paul Ritch; Laurence H Baker; Jean Y Blay; Kenneth R Hande; Mary L Keohan; Brian L Samuels; Scott Schuetze; Claudia Lebedinsky; Yusri A Elsayed; Miguel A Izquierdo; Javier Gómez; Youn C Park; Axel Le Cesne
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

View more
  4 in total

1.  Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group.

Authors:  J Khalifa; M Ouali; L Chaltiel; S Le Guellec; A Le Cesne; J-Y Blay; P Cousin; L Chaigneau; E Bompas; S Piperno-Neumann; B Bui-Nguyen; M Rios; J-P Delord; N Penel; C Chevreau
Journal:  BMC Cancer       Date:  2015-10-15       Impact factor: 4.430

Review 2.  Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas.

Authors:  Federica Recine; Alberto Bongiovanni; Nada Riva; Valentina Fausti; Alessandro De Vita; Laura Mercatali; Chiara Liverani; Giacomo Miserocchi; Dino Amadori; Toni Ibrahim
Journal:  Onco Targets Ther       Date:  2017-02-23       Impact factor: 4.147

3.  Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience.

Authors:  Alice Levard; Olfa Derbel; Pierre Méeus; Dominique Ranchère; Isabelle Ray-Coquard; Jean-Yves Blay; Philippe A Cassier
Journal:  BMC Cancer       Date:  2013-03-11       Impact factor: 4.430

4.  Complete response after rechallenge with trabectedin in a patient with previously responding high-grade undifferentiated sarcoma.

Authors:  Giacomo G Baldi; Samantha Di Donato; Rossana Fargnoli; Manjola Dona; Rossella Bertulli; Elisabetta Parisi; Lorenzo Fantini; Marta Sbaraglia; Mauro Panella
Journal:  Anticancer Drugs       Date:  2016-10       Impact factor: 2.248

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.